Budesonide therapy in preterm infants to prevent bronchopulmonary dysplasia

Shou Y. Wu, Chung M. Chen, Yung T. Kuo, Tsu F. Yeh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Severe bronchopulmonary dysplasia (BPD) is common disease, especially for the tiniest infants with gestational age <27 weeks whose mothers did not receive adequate antenatal steroid prophylaxis. Systemic corticosteroids have been demonstrated to be effective in the prevention of BPD, but their adverse effects prevent routine use. The results of inhaled steroid therapy in intubated premature infants are disappointing. In a pilot study, infants in the treatment group who received early intratracheal instillation of budesonide by using surfactant as a vehicle required significantly less ventilator supportduring the first 2 weeks than infants in the control group. The combined outcome of deaths or BPD was significantly lower in the treatment group than in the control group. No clinically significant adverse effects from the treatment were observed during the study. The results are encouraging, and a large sample multicenter trial is warranted.

Original languageEnglish
JournalNeoReviews
Volume13
Issue number8
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Budesonide
Bronchopulmonary Dysplasia
Premature Infants
Steroids
Control Groups
Therapeutics
Surface-Active Agents
Gestational Age
Multicenter Studies
Adrenal Cortex Hormones
Mothers

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Budesonide therapy in preterm infants to prevent bronchopulmonary dysplasia. / Wu, Shou Y.; Chen, Chung M.; Kuo, Yung T.; Yeh, Tsu F.

In: NeoReviews, Vol. 13, No. 8, 08.2012.

Research output: Contribution to journalArticle

@article{6e6b73e8669a4a10890da09e6072ab6f,
title = "Budesonide therapy in preterm infants to prevent bronchopulmonary dysplasia",
abstract = "Severe bronchopulmonary dysplasia (BPD) is common disease, especially for the tiniest infants with gestational age <27 weeks whose mothers did not receive adequate antenatal steroid prophylaxis. Systemic corticosteroids have been demonstrated to be effective in the prevention of BPD, but their adverse effects prevent routine use. The results of inhaled steroid therapy in intubated premature infants are disappointing. In a pilot study, infants in the treatment group who received early intratracheal instillation of budesonide by using surfactant as a vehicle required significantly less ventilator supportduring the first 2 weeks than infants in the control group. The combined outcome of deaths or BPD was significantly lower in the treatment group than in the control group. No clinically significant adverse effects from the treatment were observed during the study. The results are encouraging, and a large sample multicenter trial is warranted.",
author = "Wu, {Shou Y.} and Chen, {Chung M.} and Kuo, {Yung T.} and Yeh, {Tsu F.}",
year = "2012",
month = "8",
doi = "10.1542/neo.13-8-e467",
language = "English",
volume = "13",
journal = "Pediatrics in Review",
issn = "0191-9601",
publisher = "American Academy of Pediatrics",
number = "8",

}

TY - JOUR

T1 - Budesonide therapy in preterm infants to prevent bronchopulmonary dysplasia

AU - Wu, Shou Y.

AU - Chen, Chung M.

AU - Kuo, Yung T.

AU - Yeh, Tsu F.

PY - 2012/8

Y1 - 2012/8

N2 - Severe bronchopulmonary dysplasia (BPD) is common disease, especially for the tiniest infants with gestational age <27 weeks whose mothers did not receive adequate antenatal steroid prophylaxis. Systemic corticosteroids have been demonstrated to be effective in the prevention of BPD, but their adverse effects prevent routine use. The results of inhaled steroid therapy in intubated premature infants are disappointing. In a pilot study, infants in the treatment group who received early intratracheal instillation of budesonide by using surfactant as a vehicle required significantly less ventilator supportduring the first 2 weeks than infants in the control group. The combined outcome of deaths or BPD was significantly lower in the treatment group than in the control group. No clinically significant adverse effects from the treatment were observed during the study. The results are encouraging, and a large sample multicenter trial is warranted.

AB - Severe bronchopulmonary dysplasia (BPD) is common disease, especially for the tiniest infants with gestational age <27 weeks whose mothers did not receive adequate antenatal steroid prophylaxis. Systemic corticosteroids have been demonstrated to be effective in the prevention of BPD, but their adverse effects prevent routine use. The results of inhaled steroid therapy in intubated premature infants are disappointing. In a pilot study, infants in the treatment group who received early intratracheal instillation of budesonide by using surfactant as a vehicle required significantly less ventilator supportduring the first 2 weeks than infants in the control group. The combined outcome of deaths or BPD was significantly lower in the treatment group than in the control group. No clinically significant adverse effects from the treatment were observed during the study. The results are encouraging, and a large sample multicenter trial is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84865659819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865659819&partnerID=8YFLogxK

U2 - 10.1542/neo.13-8-e467

DO - 10.1542/neo.13-8-e467

M3 - Article

VL - 13

JO - Pediatrics in Review

JF - Pediatrics in Review

SN - 0191-9601

IS - 8

ER -